coin funding Top People also ask

Survey: More than 40% of analysts expect the Bank of Japan to raise interest rates this month, but most think that January next year is the best time. According to the latest survey, observers of the Bank of Japan predict that January is the most likely time to raise interest rates next time, but more than 40% of the respondents still expect to take action next week. According to the survey, about 52% of the 52 economists surveyed expect the Bank of Japan to raise the policy interest rate from 0.25% in January, compared with 32% in the last survey. About 44% of the respondents expect the central bank to take action at the end of the two-day meeting on December 19, down from 53% in the last survey. The survey results show that observers believe that the Bank of Japan's policy meeting this month is likely to move or not to move to a large extent. About 88% of the respondents said that the earliest possible time to raise interest rates in their risk scenarios is next week. Another equally high data shows that Japan's economic and price environment will justify raising interest rates this month.Meitu, a Hong Kong stock company, rose more than 10% in intraday trading, with turnover exceeding HK$ 400 million.FTSE China A50 index futures rose 1%.

Beijing Haidian Joy City will open on December 21st. According to WeChat official account news of "Beijing Haidian" WeChat, Haidian Joy City, the fourth joy city in Beijing, will open on December 21st. At present, many brands have come to an end, and the merchants in the venue have entered the preparations for opening. It is understood that Haidian Joy City is expected to introduce more than 280 brands.The Nikkei 225 index closed at 39,881.10 points in early trading, up 1.29%.The Hang Seng Index rose more than 1%, the Hang Seng Technology Index rose 1.47%, and the technology stocks strengthened.

The next "explosion point" of biomedicine may appear in Shenzhen. "China's pharmaceutical innovation ranks first in the second echelon in the world in terms of the quantitative indicators of R&D pipelines and listed new drugs." A few days ago, Song Ruilin, executive president of China Pharmaceutical Innovation Promotion Association, held the "Star of the Bay Area" biomedical source innovation conference in Shenzhen, and believed that China's pharmaceutical research and industrial development were entering a new stage of innovation. Chen Qiyu, vice president of China Pharmaceutical Innovation Promotion Association and executive director and co-CEO of Fosun International, said that Shenzhen has great advantages and development momentum in linking Greater Bay Area's urban development and AI technology. By leveraging the resources in the Bay Area and making good use of these advantages, it is possible to find a new fulcrum in the future biomedical R&D innovation track, and the next "explosion point" of biomedicine is likely to appear in Shenzhen.The Chinese medicine sector collectively pulled up Panlong Pharmaceutical's linear daily limit, Panlong Pharmaceutical's linear daily limit, Xiangxue Pharmaceutical, Kunyao Group, Huasen Pharmaceutical, Jingxin Pharmaceutical, Xinguang Pharmaceutical and Changyao Holdings followed suit.The negative spread of 10-year national debt between China and the United States has expanded to nearly 250BP, which is the largest in more than 22 years.